PRELIMINARY PHARMACOLOGICAL SCREENING OF SYNTHESISZED DRUGS FOR ITS ANTIDEPRESSANT ACTIVITY.
Depressive illness in people is associated with both mental disease and physical signs and changes. The effectiveness plateau experienced with conventional antidepressants, such as monoamine oxidase inhibitors and tricyclic antidepressants, persists despite the extensive use of new antidepressants in clinical settings in recent years. Although animal behavioural models of psychiatric diseases cannot accurately mimic human psychopathology, they can be used to assess the behavioural changes brought on by medications and to propose theories regarding the functioning of the central nervous system and how they relate to mental disorders. This ought to result in a clearer understanding of the therapeutic potential of psychotropic medications and a more heuristic classification of those substances. Animal models that mimic different elements of depressive diseases are responsive to the antidepressant effects of medications. In order to treat depression more effectively, quickly, with the fewest side effects, and with ease of dosage, a perfect antidepressant must be found. The preliminary pharmacological screening of the synthesised derivatives for the drug's antidepressant action was the following phase, which was then completed.
KEYWORDS: Depression, Antidepression Activity, 2-substituted 1,3,4-oxadiazino[(6,5-b) indole